Abstract ERa function is crucial for the development of normal mammary gland as well as in the process of progression of breast cancer cells. Signals that target receptor levels contribute to regulate estrogens effects in the cells. An intricate cross-regulation has been documented between ERa and TGF-b down-stream molecules: SMAD2, SMAD3, and SMAD4, that can bind ERa and regulate their signaling. Thus, identification of natural anticancer drugs able to influence the latter molecule might provide alternative choices for breast cancer treatment. Taking into account our previous published data we wanted to study the effect of 5-Methoxypsoralen (bergapten) on ERa and on TGF-b pathway. We reported that bergapten, a coumarin containing compound, effectively depletes ERa in MCF-7 breast cancer sensitive cells and in tamoxifen-resistant clone. The decrease of ERa protein after bergapten treatment results from the ubiquitine-proteasome pathway as demonstrated by the use of MG-132. IP experiments with ER antibody, demonstrated that the protein has physical interaction with SMAD4 and poly-ubiquitine and the amount of ubiquitinated receptor, linked to SMAD4, is greater under bergapten. The crucial role played by SMAD4, in this process, emerges from the observation that in breast cancer cells, silencing of SMAD4, resulted in increased expression of endogenous ERa in both control and bergapten-treated cells, compared to wild-type cells. The same results were confirmed in siRNA TGF-b RII cells. The results suggest a novel negative regulation of ERa by TGF-b/SMAD4 in breast cancer cells and indicate that the SMAD4 protein is involved in the degradation of ERa induced by bergapten. We propose that bergapten may efficiently act as a natural antitumoral agent, able to deplete ERa from breast cancer tamoxifen-sensitive and resistant cells, thereby retraining the effect of membrane signals targeting ERa and in such way its mitogenic potentiality. 
Introduction
Estrogens have been recognized as a key carcinogenic factor in breast cancer. Ligands of estrogen receptors (ERs) induce a conformational change that leads the dissociation of HSP90 followed by ERa dimerization, and binding to estrogen response elements in estrogens-responsive genes.
Agonists and antagonists-bound ER recruit either coactivators or corepressors, respectively, regulating gene transcription.
Gene amplification or overexpression of ERa was found in some breast cancer. Approximately 70 % of breast cancers are ERa positive and estrogen dependent. Moreover, the ER status is a basic prognostic marker for primary invasive breast cancer and an indicator for an individual hormonal therapy. The most commonly used anti-estrogens: OH-tamoxifen and ICI 182,780, block estrogenstimulated tumor growth and have demonstrated efficacy for treatment and prevention of ER-positive breast cancer [1, 2] . However, long-term tamoxifen treatment is associated with estrogen-like action in endometrial tissue leading to a high risk for development of uterine adenocarcinoma. In addition, development of acquired resistance to tamoxifen represents the major clinical problem during endocrine treatment in ER-positive breast cancer. A number of studies have suggested that enhanced growth factor signaling, via various signal transduction pathways, may account for endocrine resistant breast tumor growth [3, 4] .
In fact, altered expression and activation of EGFR/HER2, IGF-1R and their key downstream signaling components MAPK/ERK (mitogen activated protein kinases/ extracellular signaling regulated kinases) and PI3K/Akt (phosphatidylinositol-3-kinase/protein kinase B) can elicit anti-estrogen resistance through crosstalk with ER signaling [5] . Thus, identification of novel anti-estrogen agents may provide alternative choices for breast cancer treatment. Currently, there is a huge scientific and commercial interest in the discovery of potent, safe, and selective anti-cancer drugs. Coumarins are natural compounds found in many plants that possess medical value by itself and its modified derivatives.
They belong to the flavonoid class of plant secondary metabolites, which have been found to exhibit a variety of biological activities, usually associated with low toxicity addressing considerable interest because of their diverse pharmacological properties like anti-HIV [6] , anti-coagulant [7] , anti-bacterial [8] , anti-oxidant [9] , dyslipidemic, and anti-tumoral effects [10] . Among these properties, cytotoxic effects were most extensively examined [11, 12] . Recently, it has been reported that neo-tanshinlactone, a coumarin containing compound, showed significant inhibition against two ER ? human breast cancer cell lines and was ten-fold more potent and 20-fold more selective than Tamoxifen [13] .
In addition, our data have demonstrated how 5-methoxypsoralen (bergapten), exerts both anti-proliferative effects and induces pro-apoptotic responses in human breast cancer cells. Besides, in ER-positive MCF-7 cells 5-methoxypsoralen ''per se'' is also able to counteract the stimulatory action of IGF-I/E2 on breast cancer cell growth and progression [14] .
In addition, in established breast cancer cell lines, a correlation has been observed between ER content and sensitivity to transforming growth factor beta (TGF-b) [15] . The role of TGF-b in breast cancer is ambiguous, since it was shown to display both tumor-suppressing and enhancing effects. However, the downstream signaling components of this growth factor: SMAD2, SMAD3, and SMAD4 have been previously reported to bind ER and to regulate ER signaling [16, 17] .
In the present study, we have demonstrated how 5-methoxypsoralen in breast cancer Tamoxifen-sensitive and Tamoxifen-resistant cells is able to deplete ER protein, through a degradative process, that sees the involvement of the SMAD4 protein.
Materials and methods

Materials
DMEM/F12, RPMI 1640, MEM, L-glutamine, penicillin, streptomycin, fetal bovine serum, BSA, and PBS were purchased from Eurobio (Les Ullis Cedex, France). Triazol reagent was obtained from Invitrogen (Carlsbad, CA), and FuGENE 6 was from Roche Applied Science (Indianapolis, IN). Taq DNA polymerase was provided by Promega Corp. (Madison, WI). 5-methoxypsoralen, Estradiol, MG-132 were purchased from SIGMA (Milan, ITALY).
Antibodies against ERa/cyclin, D1/GAPDH/lamin, B/Ub/ TGFb, and RII/phospho-ERK/ERK/phospho-JNK/JNK were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against SMAD2/SMAD3/phospho-SMAD3/SMAD4/phospho-p38 MAPK/p38 MAPK, from EPITOMICS, Inc. (California) and anti-phospho Smad2 from NOVUS BIOLOGICALS, LLC (Littleton, CO, USA).
Cell cultures and treatments MCF-7 and ZR-75 breast cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA), and maintained as recommended. Tamoxifen-resistant MCF7-TR1 cells were generated in the laboratory of Dr. Fuqua as described [18] .
Cell proliferation assays
Cell proliferation was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan (MTT) assay as described [19] . Data are representative of three-independent experiments, performed in triplicate.
Transient transfection experiment
MDA-MB231 cells were transfected in SFM with pHEGO (1 lg/well), contains the full-length ERa cDNA, using FuGENE6 for 24 h. Luciferase activities were assayed as described [20] .
Immunoprecipitation and western blot analysis Cytoplasmic and nuclear fractions of cellular protein extract were obtained as previously described [21, 22] . Proteins were resolved on an 8 % sodium dodecyl sulfate (SDS)-polyacrylamide gel, transferred to a nitrocellulose membrane by electroblotting and probed overnight at 4°C with the antibody indicated in the figure legends. RNA interference MCF-7 cells were co-transfected with RNA duplex of stealth RNAi-targeted human SMAD4 or TGF-b type II receptor mRNA or with stealth RNAi-negative control using Lipofectamine 2000 as recommended [23] .
Anchorage-independent soft agar growth assays Soft agar growth assays were conducted as described in the work of Giordano C and colleagues. Data are the mean colony number of three plates and representative of twoindependent experiments [24] .
Statistical analysis
All data were expressed as the mean ±SD of at least threeindependent experiments. The data were analyzed by analysis of variance using the STATPAC computer program. (Fig. 1a) enhances the anti-proliferative activity of OH-Tamoxifen. In addition, in MCF-7/ TAM Res clone bergapten, after 96 h, antagonizes the stimulatory action of anti-estrogen even at low doses (5 and 10 lM) (Fig. 1b) .
Bergapten down-regulates ER a protein content and decreases estrogen response gene expression
To test the effect of the drug on ERa expression, we treated for 24 h breast cancer cells with the same doses of bergapten used for cell growth. Western Blot analysis of whole-cell lysates of MCF-7 and ZR-75 cells showed that the protein content of ERa was decreased by the highest concentrations of bergapten ( Fig. 2) . At the same time, we examined the effect of the treatment on ERa-mediated gene expression. The incubation with bergapten reduces cyclin D1 protein in both cell types, taking as positive control the cyclin D1 expression upon E 2 exposure. The same downregulatory effect was reproduced in MCF-7/TAM Res cells either in the absence or in the presence of OH-Tamoxifen maintained during the experimental time (Fig. 2) . To ascertain if bergapten-mediated ER down-regulation was due to inhibitory effect induced on ER-gene transcription, we performed RT-PCR to detect ERa mRNA level upon the cumarine exposure. As shown in Fig. 3 , bergapten does not affect ERa mRNA levels in MCF-7, ZR-75, and MCF-7/TAM Res cells. This reasonably addressed the potential role of post-trascriptional mechanisms in determining the bergapten-induced ERa downregulation.
Bergapten promotes ERa degradation via the ubiquitine-proteasome pathway
To evaluate the potential molecular mechanism by which bergapten inhibits ER protein expression, we focused on ubiquitin-proteasome pathway. MCF-7, ZR-75, and MCF-7/ TAM Res cells were treated with 20 lM and 50 lM bergapten in the presence or absence of the proteasomal inhibitor MG-132 (5 lM). In all three cell lines, reduction in ERa by bergapten was prevented by the proteasomal inhibitor MG-132, suggesting that bergapten could induce ERa degradation via the proteasome degradative pathway (Fig. 4) .
All these data were confirmed in ER negative MDA-MB 231 cells, overexpressing ectopically the ERa through transient trasfection (Fig. 4) . Indeed, MG-132 incubated with bergapten increases the ERa level compared to that obtained by bergapten alone (Fig. 4) . Furthermore, in order to evaluate in which cellular compartment ERa degradation occurs we performed Western Blot analysis in extranuclear and nuclear fractions of MCF-7, ZR-75, and MCF-7/TAM Res cells under bergapten treatment. The lowering of ERa induced by psoralen (20 and 50 lM) occurs prevalently in the cytoplasmic fraction of breast cancer cells (Fig. 5) .
All results revealed that bergapten affects ERa stability in both wild-type breast cancer cells than in Tamoxifenresistant clone.
Influence of SMAD4 in the bergapten-induced ERa ubiquitination ER protein is a cross-road of different intracellular signalings which can modulate ER activity during breast tumorigenesis. Recently, it has been reported how ERa may directly interact with SMADs, the effectors of the TGF-b pathway and, in this respect, to be inversely related to them [16, 17] . In our study, we wanted to ascertain if bergapten, by depleting ERa, might also affect the expression levels of SMAD proteins. Western Blot analysis performed in MCF-7 and MCF-7/TAM Res cells reveals that, while SMAD3 tends to decrease, SMAD4 protein is maintained upon bergapten treatment, resulting in an increase of the SMAD4/SMAD3 ratio as illustrated in the figure 6 a, b. Furthermore, immunoprecipitation experiments with antiERa antibody followed by Immunoblotting with anti-SMAD4 and anti-Poly-Ub antibodies show that ER/ SMAD4/Poly-Ub are co-associated in a tripartite complex and that bergapten enhances the amount of SMAD4 and Poly-Ub complexed to ERa (Fig. 7a) .
In order to further evaluate the role of SMAD4 in the ER-ubiquitination process we targeted SMAD4 with siR-NA. IP experiments of MCF-7 cell lysates with anti-ERa antibody followed by Western Blotting for ERa, showed that SMAD4 knockdown induces a greater retention of ERa, so as to be longer expressed, compared to that one obtained in wild-type cells. This addresses how in the latter circumstance a minor ER-ubiquitination occurs (Fig. 8a, b) .
A higher expression of ERa in siRNA SMAD4 MCF-7 cells, compared to wild-type cells, was also confirmed in whole cell lysate by Western Blot (Fig. 8c) .
The results confirm that SMAD4 physically interact with ERa and expression of SMAD4 is necessary to mediate the bergapten-induced ER degradation. Taking into account that SMAD4 is a down-stream signaling of TGF-b, we wanted to evaluate the role of TGF-b receptor on ERa protein content both in bergapten-treated and untreated MCF-7 cells. To this aim, we transiently transfected MCF-7 cells with siRNA TGFbeta-RII and we stimulated the cells for short time with the drug to assess the phosphorylation signals down-stream the TGF-b pathway. It is worth to mention how, in this circumstance, as expected, we observed a reduction of SMAD4 and a marked up-regulation of ERa compared to the co (Fig. 9a) .
In addition, in cells bearing siRNA TGF-b RII under bergapten treatment it has been shown a reduction of phospho-SMAD2 and phospho-SMAD3, with respect to scrambled siRNA control (Fig. 9a) .
To evaluate the potential involvement of MAPKs in the phosphorylation of SMADs under bergapten treatment, we reprobed the filters for anti-p38 kinase, anti-p-ERK1/2, and for anti-p-JNK.
In these experimental conditions, bergapten was able to up-regulate p-JNK, which appears clearly blunted in the presence of siRNA TGF-b RII, while no substantially modifications were reported under bergapten for p-ERK1/2 and p38MAPK (Fig. 9c) .
Indeed, the use of the specific JNK-kinase inhibitor SP600125 reverses the p-SMAD2 and p-SMAD3 activation and leads to an increase of ERa protein (Fig. 9e) . Thus, we may conclude that bergapten is able to stimulate TGF-b signaling, which through JNK activation, phosphorylates SMAD2 and SMAD3. These events lead to an up-regulation of SMAD4 protein, that binds ERa and drives its ubiquitination.
Bergapten influences the anchorage-independent growth induced by Estradiol
We next have evaluated the effects of bergapten on the anchorage-independent growth upon E 2 -exposure of MCF-7 and MCF-7/TAM Res clone. Our data have shown that psoralen is able to antagonize the stimulatory action induced by E 2 on cell growth in soft agar, and, in a higher extent, in Tamoxifen-resistant clone (Fig. 10) .
Discussion
ER has become an important target in the treatment of hormones-responsive breast cancer. Unfortunately, most patients initially responding to anti-estrogen therapies develop pharmacological resistance. The potential mechanisms of endocrine resistance are not fully understood, but multifactorial determinants may be involved, such as the growth factor signaling and altered ER regulation.
Therefore, depletion of ERa from breast cancer may give particularly powerful advance to block mitogenic signals, even those coming from the ER/growth factor crosstalk, preventing the development of endocrine resistance.
We showed previously that cumarine-derivate compound: 5-MOP (bergapten) inhibits human breast cancer growth, by increasing p53 and p21 expression, and induces a functional activation of pro-apoptotic response [14] . In this study, we reported that 5-MOP in breast cancer cells is able to down-regulate ERa protein, without affecting mRNA-ERa level, and to decrease estrogen response gene expression such as cyclin D1. This suggests, how, very likely, the down-regulation of ERa upon exposure to bergapten does not involve a transcriptional mechanism. Indeed, the use of MG-132, a proteasome inhibitor, It is extremely intriguing to observe that the abovereported effect of bergapten on ERa degradation is reproduced in breast cancer Tamoxifen-resistant cells, where we have reported a marked decrease of cell proliferation, evidencing an efficient response of these cells to the effect of psoralen.
It is worth to mention how the enhanced anchorageindependent growth upon E 2 exposure is drastically attenuated in the presence of the combined exposure of bergapten, emphasizing, furthermore, the boostering action of the psoralen on ERa-degradation in breast cancer cells.
These results reflect the anti-tumoral properties of the molecule and call other published data demonstrating how some coumarin derivatives can be potent inhibitors of proliferation of aromatase and ER positive breast cancer cells [25, 26] . The amount of ERa protein in the cell is a major determinant of the regulation of its own transcriptional activity. Steady state of ERa level is maintained by a dynamic balance between protein synthesis and breakdown. Many factors regulate the endogenous levels of ERa in the cells and this, in turn, influences the Several observations have documented the crosstalk between ERa-activity and TGF-b signaling. Indeed, previous reports have demonstrated how ERa is able to physically interact with SMAD2, SMAD3, and SMAD4 and to abrogate TGF-b signaling cascade [16, 17, 27] .
On the other hand, while TGF-b signaling has been demonstrated to stimulate ERa transcriptional activity, the complex of SMAD3 and SMAD4 inhibits its activity [16, 28] .
In our study, we proved that in breast cancer-treated cells the down-regulation of ERa coincides with the increase of SMAD4/SMAD3 ratio, implying a functional relationship between SMAD4 and ER.
Indeed, immunoprecipitation assay reveals that ERa/ SMAD4 and poly-ubiquitine co-associated in a tripartite complex. As expected, the amount of ERa in the immunoprecipitate is lowered by the treatment, while the levels of SMAD4 and poly-ubiquitine present in the complex are markedly higher, addressing the important role of the latter two proteins in sustaining ERa-degradation.
The crucial role played by SMAD4 in ER-depletion emerges from the evidence that in the presence of its silencing the endogenous ERa is enhanced, being better preserved in both control and treated-cells, than in wildtype cells.
The phenomenon was also observed in MCF-7 cells silenced for TGF-b RII. In the same vein, IP experiments confirmed that SMAD4 silenced in MCF-7 cells lowers the ubiquitination of ERa, thereby highlighting a negative relationship between the two proteins. In addition, in the presence of the JNK-specific inhibitor the activation of SMAD proteins was partially reversed, while concomitantly the ERa content was enhanced.
These findings suggest that SMAD4 protein, downstream the TGF-b signaling, is crucially involved in the degradative process of the receptor.
In addition, the observation that SMAD4 is up-regulated following bergapten treatment, highlights a new molecular mechanism through which psoralen might affect ERa stability and thereby regulate breast cancer cell progression.
Results in the same direction, have been published regarding the involvement of proteasomal degradation of ERa by TGF-b in breast cancer cells. So, all this brings again to a functional interplay between TGF-b and ERsignaling in breast cancer [29] .
Finally, apart from the apoptotic function of bergapten, as we previously documented in breast cancer cells [14] , the present article has highlighted a novel role of the molecule in regulating ERa-protein stability via the ubiquitin-proteasome pathway.
This study, once again, draws attention to the anti-cancer properties of psoralen, emphasizing how the molecule can unfold its functional activity even in the absence of photoactivation.
Based on what we just said, we propose that bergapten may efficiently act as a natural anti-tumoral agent, able to deplete ERa from breast cancer tamoxifen-sensitive and resistant cells thereby preventing crosstalk between the receptor and growth factor mitogenic signaling.
